Aldeyra Therapeutics, Inc. 8-K

What Happened
Aldeyra Therapeutics, Inc. (ALDX) filed an 8-K on April 20, 2026 (Item 5.02) reporting that Board member Martin J. Joyce notified the company he will not stand for re‑election at the 2026 annual meeting of stockholders. Mr. Joyce will continue to serve on the board until his term expires at the 2026 annual meeting. The filing states his decision was not the result of any disagreement with Aldeyra.

Key Details

• Date of notice: April 20, 2026.
• Director: Martin J. Joyce.
• Status: Will serve until his term expires at the 2026 annual meeting; not standing for re‑election.
• Company note: Decision was not due to any disagreement with Aldeyra; no successor or replacement was named in the filing.

Why It Matters
This is a governance update for investors: a sitting director has chosen not to seek another term, which could lead to a board seat opening after the 2026 annual meeting. The filing contains no indication of disagreement or immediate operational impact. Shareholders may watch for future announcements about board nominations or replacements ahead of the annual meeting.